| |
A SPECIAL
ANNOUNCEMENT FROM: |
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Personalizing
medicine by utilizing companion (and complementary) diagnostics has
greatly impacted patient outcomes for those with cancer. Can companion
diagnostics make a similar impact across a wider spectrum of diseases?
Nearly
50 percent of all drugs in clinical development fail due to lack of
efficacy. Companion diagnostics may represent a viable way to boost drug
development effectiveness.
Read more about promising therapeutic areas, outside of oncology, where companion diagnostics may play an important role.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COVANCE AND LABCORP HAVE SUPPORTED MORE THAN 70% OF ALL FDA-APPROVED COMPANION AND COMPLEMENTARY DIAGNOSTIC ASSAYS.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Covance Inc., headquartered in Princeton, NJ, USA is the drug development
business of Laboratory Corporation of America Holdings (LabCorp).
COVANCE is a registered trademark and the marketing name for Covance Inc.
and its subsidiaries around the world.
Copyright © 2017 Covance Inc. All rights reserved.
|
Covance Inc., 210 Carnegie Center Princeton, NJ 08540-6233 USA
THE AMERICAS: +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440
EUROPE/AFRICA: +00.800.2682.2682 +44.1423.500888
ASIA PACIFIC: +800.6568.3000 +65.6.5686588
|
|
|
